Regeneron Pharmaceuticals Stock Analysis

REGN Stock  USD 962.49  3.81  0.39%   
Regeneron Pharmaceuticals is overvalued with Real Value of 692.99 and Target Price of 912.52. The main objective of Regeneron Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Regeneron Pharmaceuticals is worth, separate from its market price. There are two main types of Regeneron Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Regeneron Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Regeneron Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Regeneron Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Regeneron Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Regeneron Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Regeneron Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Regeneron Stock Analysis Notes

About 89.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 242.47. The company has Price/Earnings To Growth (PEG) ratio of 1.56. Regeneron Pharmaceuticals recorded earning per share (EPS) of 34.81. The entity had not issued any dividends in recent years. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10915 people. To find out more about Regeneron Pharmaceuticals contact Leonard Schleifer at 914 847 7000 or learn more at https://www.regeneron.com.

Regeneron Pharmaceuticals Quarterly Total Revenue

3.43 Billion

Regeneron Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Regeneron Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Regeneron Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Over 89.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Latest Global Cancer Immunotherapy Market SizeShare Worth USD 314.4 Billion by 2032 at a 7.2 percent CAGR Custom Market Insights

Regeneron Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Regeneron Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regeneron Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
2nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
2nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Regeneron Largest EPS Surprises

Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2004-07-26
2004-06-30-0.3-0.260.0413 
1999-10-28
1999-09-30-0.2-0.160.0420 
2008-11-04
2008-09-30-0.32-0.270.0515 
View All Earnings Estimates

Regeneron Pharmaceuticals Thematic Classifications

In addition to having Regeneron Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services
Cancer Fighters Idea
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Regeneron Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Wellington Management Company Llp2023-12-31
1.1 M
Northern Trust Corp2023-09-30
1.1 M
Norges Bank2023-12-31
1.1 M
Morgan Stanley - Brokerage Accounts2023-09-30
971 K
Bank Of New York Mellon Corp2023-09-30
967.4 K
American Century Companies Inc2023-12-31
931.3 K
Bank Of America Corp2023-09-30
836.9 K
Legal & General Group Plc2023-09-30
820.2 K
Amvescap Plc.2023-09-30
743.3 K
Fmr Inc2023-09-30
9.8 M
Blackrock Inc2023-09-30
8.9 M
Note, although Regeneron Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Regeneron Market Capitalization

The company currently falls under 'Mega-Cap' category with a current market capitalization of 105.41 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regeneron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Regeneron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Regeneron Profitablity

Regeneron Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Regeneron Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Regeneron Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Regeneron Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Regeneron Pharmaceuticals' profitability requires more research than a typical breakdown of Regeneron Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.3 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.
Last ReportedProjected for 2024
Return On Capital Employed 0.14  0.14 
Return On Assets 0.12  0.13 
Return On Equity 0.15  0.16 

Management Efficiency

Regeneron Pharmaceuticals has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1626 %, meaning that it created $0.1626 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Capital Employed is likely to grow to 0.14. Also, Return On Assets is likely to grow to 0.13. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 29th of March 2024, Fixed Asset Turnover is likely to grow to 3.32, while Other Current Assets are likely to drop about 203.9 M.
Last ReportedProjected for 2024
Price Book Value Ratio 3.84  5.25 
Enterprise Value Multiple 19.46  26.38 
Price Fair Value 3.84  5.25 
The analysis of Regeneron Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Regeneron Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Regeneron Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.11

Technical Drivers

As of the 29th of March, Regeneron Pharmaceuticals holds the Semi Deviation of 0.6298, coefficient of variation of 497.43, and Risk Adjusted Performance of 0.1161. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regeneron Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Regeneron Pharmaceuticals, which can be compared to its competitors. Please check Regeneron Pharmaceuticals downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Regeneron Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 962.49 per share. Given that Regeneron Pharmaceuticals has jensen alpha of 0.1179, we recommend you to check out Regeneron Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Regeneron Pharmaceuticals Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Regeneron Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Regeneron Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Regeneron Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Regeneron Pharmaceuticals Outstanding Bonds

Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Regeneron Pharmaceuticals Predictive Daily Indicators

Regeneron Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regeneron Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Regeneron Pharmaceuticals Corporate Filings

F4
15th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
5th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
28th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
26th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
20th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
16th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
13th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
12th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Regeneron Pharmaceuticals Forecast Models

Regeneron Pharmaceuticals' time-series forecasting models are one of many Regeneron Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Regeneron Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Regeneron Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Regeneron Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regeneron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Regeneron Pharmaceuticals. By using and applying Regeneron Stock analysis, traders can create a robust methodology for identifying Regeneron entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin 0.32  0.34 
Operating Profit Margin 0.31  0.32 
Net Profit Margin 0.30  0.32 
Gross Profit Margin 0.86  0.64 

Current Regeneron Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Regeneron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Regeneron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
912.52Buy28Odds
Regeneron Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Regeneron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Regeneron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Regeneron Pharmaceuticals, talking to its executives and customers, or listening to Regeneron conference calls.
Regeneron Analyst Advice Details

Regeneron Stock Analysis Indicators

Regeneron Pharmaceuticals stock analysis indicators help investors evaluate how Regeneron Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Regeneron Pharmaceuticals shares will generate the highest return on investment. By understating and applying Regeneron Pharmaceuticals stock analysis, traders can identify Regeneron Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow3.1 B
Long Term DebtB
Common Stock Shares Outstanding113.7 M
Total Stockholder Equity26 B
Tax Provision385.3 M
Quarterly Earnings Growth Y O Y-0.029
Property Plant And Equipment Net4.1 B
Cash And Short Term Investments10.8 B
Cash2.7 B
Accounts Payable606.6 M
Net Debt-27.1 M
50 Day M A957.906
Total Current Liabilities3.4 B
Other Operating ExpensesB
Non Current Assets Total13.6 B
Forward Price Earnings21.5054
Non Currrent Assets Other444.1 M
Stock Based Compensation885 M
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Earnings Share
34.81
Revenue Per Share
122.935
Quarterly Revenue Growth
0.006
Return On Assets
0.0849
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.